Zevra Therapeutics, Inc. (ZVRA)
(Delayed Data from NSDQ)
$6.54 USD
+0.31 (4.98%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $6.55 +0.01 (0.15%) 4:32 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ZVRA 6.54 +0.31(4.98%)
Will ZVRA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ZVRA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ZVRA
Zevra (ZVRA) Rises on Update on Niemann-Pick Disease Type C Drug
Zevra Therapeutics (ZVRA) Surges 21.9%: Is This an Indication of Further Gains?
ZVRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zevra Therapeutics (ZVRA) Reports Q1 Loss, Lags Revenue Estimates
Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Beat Estimates
Will OptiNose (OPTN) Report Negative Q1 Earnings? What You Should Know
Other News for ZVRA
Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C
Zevra Therapeutics Expands Executive Leadership Team
Zevra appoints Rahsaan Thompson as Chief Legal Officer, Peters as CPO
Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders
Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders